A Study of TRK-170 for the Treatment of Crohn's Disease

Toray Industries, Inc123 enrolled

Overview

In Crohn's Disease Patients * To evaluate the efficacy of TRK-170 * To evaluate the PK characteristics of TRK-170 * To assess the safety of TRK-170

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

123

Conditions

Crohn's Disease

Interventions

TRK-170DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has a diagnosis of Crohn's Disease before screening * Patient has stable disease activity Exclusion Criteria: * Patient has had a clinically significant illness prior to screening * Patient with clinically significant deviations in laboratory values

Locations (13)

Belgium

Belgium, Belgium

Bulgaria

Bulgaria, Bulgaria

Czech Republic

Czech Republic, Czechia

France

France, France

Outcomes

Primary Outcomes

Crohn's Disease Activity Index

8 weeks (treatment), 4 weeks (follow-up)

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.